Hemoglobinopathy
8
3
3
1
Key Insights
Highlights
Success Rate
25% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 75/100
37.5%
3 terminated out of 8 trials
25.0%
-61.5% vs benchmark
0%
0 trials in Phase 3/4
100%
1 of 1 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (8)
Determination of Red Cell Survival in Sickle Cell Disease and Other Hemoglobinopathies Using Biotin Labeling
A Long-term Follow-up Study in Patients Who Received BEAM-101
A Phase I Study of SNH-119014 in Healthy Volunteers
T-cell Depleted Alternative Donor Transplantation
Expanded Access Protocol (EAP) Using the CliniMACS® Device for Pediatric Haplocompatible Donor Stem Cell Transplant
Bone Marrow Transplant From Related Donor for Patients With High Risk Hemoglobinopathies
Bone Marrow Transplant From Donor Using Less Toxic Conditioning for Patient With High Risk Hemoglobinopathies
Hydroxyurea to Treat Beta-Thalassemia (Cooley's Anemia)